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Antidepressants 
By Dr Michelle Bellli7gan 
learning objectives 
This article aims to provide the re ader with 
an update of: 
• The ma jor theories that are hypothesised to 
explain the patho logy of depression 
• The pharmacodynamics of the new generation 
antidepressants 
• The efficacy and onset of action of these 
newer antidepressants compared to the older 
antidepressants. 
Competencies addressed: 3.1.2, 4.2.1 
Depression is the fourth most common prob lem presenting 
to GPs in Austra lia . It is est imated that 10% of peop le 
may become depressed during their lives . This lifet ime 
prevalence may be as high as 20% in women. 1 A recent 
study revea led that the most commonly prescribed 
medication for Australian women is antidepressants.1 
There are numerous neurochemical theories perta ining to 
the pathophys iology of depression and a correspond ing 
variety of drugs used in the treatment of this complex 
condit ion Tricyclic antidepressants (TeAs), monoam ine 
oxidase inhibito rs (MAO ls) and mianserin dominated the 
antidepressant ma rket until the first selective serotonin 
reuptake inhibitor (SSRI), fluoxetine, was approved by the 
FDA (United States) in 1988. Since then, four more SSR ls 
and four other new antidepressants, namely venla fa xine, 
duloxetine, reboxetine and mirtazap ine, have been 
approved (refer to Table 1). 
Th is increased armentorium of antidepressants could 
lead both patients and practitioners to pose the 
following questions: 
• How do these newer ant idepressants work? 
• Are they more acceptable to pat ients in terms of 
side effects? 
• Are these newer antidepressants more effective than 
the older agents? 
• Do the newer ant idepressants have a faster onset than 
the older agents? 
This article wi II br ief ly address these questions. 
Summary of pathology of depression 
The cause of depression is yet to be fully elucidated. It has 
been proposed that depression may be due to decreased 
fun ctional amine -dependent synaptic transm ission 4 
The Monoamine Hypothesis of Depression states that 
depression is caused by a def ici ency of monoam in es, 
part icu larly noradrena li ne and serotonin , in the synaptic cleft. 
Accord ing to this hypothes is, depress ion can be al leviated 
by drugs that increase the ava ilab ility of noradrenal ine and 
serotonin .4 Di fferent types of depression are stil l be ing 
debated, i.e. Pat ient As depression may be large ly as a resu lt 
of a noradrena li ne defic iency, Patient B may be depressed 
because of seroton in deficiency, whereas Patient C's 
depressi on might be due to a deficiency of both these 
neurotransmi tters. Antidepressant therapy shou ld therefore 
be indiv idual ised accord ing to patient response 
The Monoamine Hypothesis of Depression cannot expla in 
the delay in t ime of onset of clinica l rel ief of depress ion of 
up to six to eight weeks. Th is is explained by the Receptor 
Sensitivity Hypothesis. Supe rsensi tivity is a compensatory 
response of the postsynaptic neuron when it rece ives too 
little st imulat ion . The neuron attempts to make up fo r a 
lack of stimulat ion by increas ing receptor responsiveness. 
Over time, th e postsynapt ic neuron may also compensate 
for the lack of stimu lation by synthesis ing add it ional 
rece pto r si tes 4 This process is kn own as up-regulation. 
Th is up- regulated postsynaptic state is be li eved to be 
associated wi th the cl in ica l symptoms of depress ion 
Pharmacodynamics of new generation 
antidepressants 
All the antidepressants currently ava il ab le have been 
developed in line with the Monoami ne and Receptor 
Sensit ivity Hypotheses. Desp ite hav ing varied 
pharmacodynamic actions, antidepressants increase 
neurotransmitter leve ls in the syna pt ic cleft, wh ich then 
prompts postsynaptic receptors to decrease in number 
(down-regulate) and decrease in sensitivity (desensi ti sat ion). 
Table 2 outlines the pharmaco logical di fferences among 
severa l of the older and newer ant idepressants. 
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Tab le 1. Ant idepressant Drug Classes 
(adapted from AM H3) 
Tr icyclic Amitriptyl ine Endep 
an tidepressants Clom ipram ine Anafranil, Placi/ 
(TCAs) Do th iepin DotlJep, Prothiaden 
Doxepin Deptran, Sinequan 
Imipram ine Tofrani/, To/erade 
Nortriptyline Allegron 
Trimipramine Surmontil 
Monoami ne Moclobemide Amira, Aurorix, Clobemix, 
oxidase reuptake Mohexal, Maosig 
inh ibitors (MAo ls) Phene lzine Nardil 
Tranylcypromine Pamate 
Other Mianserin Lumin, Tolvon 
Newer antidepressant classes 
Se lective seroton in Citalopram Celapram, Celiea, Ciazil, Cipramil, 
reuptake inhibitors Citalobell, Citalopram, Talam, Talohexal 
(SSRls) Escitalopram Esipram, Lexapro 
Fluoxet ine Lovan, Prozae, Auscap, Fluohexal, 
lactin, Fluoxebell 
Fluvoxam'lne Faverin. Luvox, Movox, Voxam 
Pa roxetine Aropax, Exline, Paxtine 
Sertra line Coneorz, Sertra, Eleva, loloft. Xydep 
Seroton in Venlafaxine Efexor-XR 
norad rena line Duloxetine Cymbalta 
reuptake inh ibitors 
(S NRlsl 
Selective Reboxetine Edronax 
noradrena line 
reuptake inhibitors 
(NARis) 
Noradrenerg ic Mirtazapine Avanza, Mirlalon, Remeron, 
and specific Axit30, Avanza So/Tab 
serotonerg ic 
antidepressant 
(NaSSA) 
Question 1. How do the newer 
antidepressants work? 
Selective serotonin reuptake inhibitors 
SS Rl s block the amine pump for serotonin reuptake. 4 
Paroxetine and sertraline are also associated with a 
down-regulat ion of postsynaptic beta-l-adrenoceptors.5 
The side-effects of SSRls are large ly associated with 
increa sed leve ls of seroton in interacting with postsynaptic 
5-HT2 and 5-HT3 receptors. Stimu lation of 5-HT3 receptors 
is respons ible for nausea, diarrhoea and headache, which 
often occur at the start of treatment. Agitation, akath isia, 
anxiety, panic attacks, insomnia and sexua l dysfunction 
may be re lated to an action at 5-HT2 receptors. Sexual 
dysfunction may also be due to disinhibit ion of the 
descending serotonin pathway from the brain stem through 
the spina l co rd to neurons med iating sp ina l reflexes such 
as ejaculation and orgasm. The increased seroton in release 
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inhibits sexual functioni ng." During long term therapy, the most 
troub lesome adverse effects are sexual dysfunction, weight 
gain and sleep disturbance. 5 
It is impo rtant to consider that the SSR ls have di ffe ring 
ind ividual profiles (refe r to Tab le 2). 
Gastrointestinal side effects are most frequently reported . 
Fluvoxamine and sertra line are associated with the highest 
frequency of GI disturbances. 
Serotonin noradrenaline reuptake inhibitors 
SNRls selective ly block the reupta ke of both serotonin and 
noradrena line into the presynaptic bulb. Weak effects on 
dopamine reuptake have also been reported. 5 It should 
be noted that the increased dopami ne levels are not of 
signif icance in terms of the ame lioration of depressive 
symptoms. Unlike the TeAs, however, SNRls have less alpha-
1, cholinergic or H1 receptor blocking properti es. In part icu lar, 
SNRls have fewer cardiac effects, hence they are safer in 
overdose than TCAs. 
It should be noted that the reuptake effects of venlafaxine are 
dose dependent. At low doses «150 mg/day). the dru g acts like 
the SSRls At intermediate to high doses, the addit iona l effects 
of noradrena line reuptake become more sign ifica nt. " 
Nausea, ag itation, sexual dysfunction and insomn ia at low 
doses of ven lafax ine are probab ly as a resul t of effects on 
postsynaptic serotonerg ic receptors. At interm ed iate to 
high doses, additiona l adve rse effects such as raised blood 
pressure and headache are observed. " These effects are 
probably due to an action on the noradrena line transporter. 
Selective noradrenaline reuptake inhibitors (NARis) 
The prototype drug in th is class, reboxetine, selectively inhibits 
the reupta ke of noradre naline. It has been proposed that 
reboxetine may be more effect ive in noradrenaline deficiency 
syndrome (e.g. depression assoc iated with fa tigue, apathy, 
cogn itive and somatic disturbances). or nonresponders to SSRl s. 
Adve rse effects of reboxet ine include urinary retention, 
dry mouth, sweating, pa rasthaesia and constipation. Other 
noradrenerg ic effects include: increased diastolic blood 
pressure, increased heart rate, insomnia and headache.3 
Genito urinary prob lems occurring within f ive weeks of 
commencing therapy have been described in numerous 
Adverse Drug Reactions Advisory Committee (ADRAC) 
reports . Patients prescribed reboxetine should be asked about 
symptoms of urinary obstruction and sexua l dysfunct ion so on 
after commencing therapy.' 
Noradrenergic and specific serotonergic 
antidepressants 
With the exception of the MAO Is, all an ti depressants 
have inh ibitory effects at the monoamine re uptake pump 
(either fo r seroton in, norad renaline or both). Mirtaza pine is 
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ph armacologica ll y un ique in that it is an alpha-2 -antagonist 
on the presynapt ic bulb. By inh ibiting this autorecepto r, 
mirtazapine counte racts negative feedback on the re lease of 
neu rotransmitters from storage vehic les, thereby promoting 
neurotransmitter re lease. Mirtazapine also antagonises 
post-synaptic 5-HT2 and 5-HT3 receptors the reby minimis ing 
the more common adverse effects assoc iated with th e 
SSR ls . Despite having less of the traditiona l serotonergic 
side effects, mirta za pine use is frequent ly associated with 
increa sed appeti te, we ight ga in , sedation, weakness and 
periphera l oedema.3 
Ouestion 2. Are the new generation 
antidepressants more acceptable to 
patients in terms of side-effects? 
The new generation antidepressants tend to have more 
tolerable side effect profi les than TCAs and MAO Is . As outl ined 
above, these drugs are by no means devoid of significant side 
effects. On average, 61 % of pati ents tak ing second-generation 
antidepressants experi ence at least one side effect. The 
most common are nausea, vomit ing, constipation, diarrhoea, 
dizz iness, headache and sleep lessness B 
Ven lafaxine is assoc iated with a highe r incidence of nausea 
and vomiti ng than the SSR ls. This drug is also mo re likely 
to be discont inued due to adverse effects. Sertral ine is 
more li ke ly to cause diarrhoea than citalopram, f luoxetine, 
f luvoxam ine, mirtazap ine, paroxetine or ven lafaxine. 
Mirtazap ine leads to a hig he r inci dence of we igh t ga in tha n 
fluoxet ine, paroxetine or venlafaxine B 
Ouestion 3. Are these newer 
antidepressants more effective than 
the older agents? 
Desp ite working in different ways and having different 
adverse effect profiles, ant idepressants have always been 
regarded as be ing equa lly effica cious or equipotent. None 
of the newer antidepressants have been shown to be more 
effecti ve than the tricyclics with which they have been 
compared. 4 Recently pub lished meta-ana lyses have, however, 
questioned the equipotency of the newer ant idepressants.s 
One of these studies ana lysed res ul ts of 117 randomised 
controll ed tria ls from 1991- 2007, which compa red the 
effects of 12 new generation ant idepressants in more than 
25,000 patients with major depression. The drugs tested 
were bupropion*, cita lopram, duloxet ine, esc ita lopram, 
fl uoxetine , f luvoxamine, mi lnacipran**, mirtazapine, 
paroxetine, reboxet ine, se rtraline and ven lafax ine. 10 
* on ly ava il ab le as nicotine replacement in Austral ia 
** not avai lab le in Austra lia 
Sert rali ne and escita lopram we re report ed to score high ly 
in terms of effi cacy and acce ptab il ity, wh ile reboxet ine wa s 
shown to be sign if icantly less eff icac ious than the other 11 
Tab le 2. Pha rmacolog ica l differences among severa l 
a ntidepressa nts4 
Drug Sedative Anti - Block of amine 
action muscarinic pump for: 
action Serotonin Nora-
drenaline 
TeAs 
Am itriptyl ine +++ +++ +++ 
Clom ipramine +++ ++ +++ 
Des ipram ine + + 0 
Doxepin +++ +++ ++ 
Im iprami ne ++ ++ +++ 
No rtri ptyl i ne ++ ++ +++ 
SSRls 
Ci talo pram, 0 0 +++ 
Esc ita lopram 
Fluoxet ine + + +++ 
Fluvoxamine 0 0 +++ 
Paroxetine + 0 +++ 
Sertral ine + 0 +++ 
SNRI 
Venl afaxine 0 0 +++ 
NaSSA 
Mirtazap ine +++ 0 0 
drugs studied in the meta-ana lys is. Mirtazapine and 
esc italopram were also found to be more eff icacious than 
the other drugs tested . Esc ita lopram and sertral ine showed 
the best profil e of acceptab ility, leading to signif icant ly 
fewer disconti nuations of treatment than did du loxet ine , 
fluvoxamine , paroxetine, reboxet ine and venlafaxine. 10 
Despite these new claims, it should be considered tha t 
pat ients respond in a high ly individua lised manner to 
ant idepressants. Sertraline and escita lopram might not be 
effect ive or appropriate in all patients. 
Ouestion 4. Do the newer antidepressants 
have a faster onset than the older agents? 
Speed of onset of an tidepressan ts is clinical ly important 
fo r many reasons . Oelayed onset mean s that depress ion, 
its assoc iated disabil ity and, for some patients, the 
potentia l ri sk of suic ide continue. Ea rly onset of effects may 
improve future comp liance and thus outcomes]) 
As depicted in Figure 1, neurotransmi tte r leve ls show an 
increa se wi thin the f irst week of ant idepressant therapy. 
It may however take six to eigh t weeks before patients 
experience therapeut ic benef its. It is hypothesised that the 
rate-limit ing step in th is process is the down-regu lat ion of 
up-regu lated receptors. 
Several antidepressants have claimed an earlier onset of act ion 
but none has, as yet, demonstrated this incontrovertibly. 11.1 3 
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Figure 1. Postulated neurotransm itter receptor 
hypothesis of antidepressant action 
ffl 
Receptor I Sensitivity 
..... 1 
... ~. Amoun t of NT 
Cl inical Effect 
4 6 B 
Number of weeks 
Adapred from: Srahl SM. Srahl's Essential Psychopharmacology, 
Neuroscienrific Basis and Pracrical Applications, 3rd ed. USA: 
Cambridge Universiry Press, 2008. 
Post hoc analyses of comparisons between SSRls and 
dual-action antidepressants such as mirtazapine, ven lafaxine 
and duloxetine indicate that the dual -act ion drugs may have a 
faster onset of action.13.14 Current data do not clea rl y support 
claims that one drug reduces the symptoms of depression 
faster than another, though the existing literature suggests 
that escitalopram displays some superiori ty in terms of rap idity 
of act ion .13 
Qu estions 
1. Identify the incorrect statement pertaining to the use of 
SSRls. 
al Sertraline has a higher risk of diarrhoea than any of the other SSRls. 
bl The side-effects of SSRls are largely associated with the increased 
levels of serotonin interacting with postsynaptic 5-HTI receptors. 
c) During long-term therapy, the most troublesome side effects of 
SSRls are nausea, diarrhoea and headache. 
dl (b) and (c). 
e) (a) and (b) . 
2. Which of the following antidepressa nts have a dua l-action? 
al Duloxetine. 
b) Reboxetine. 
c) Mirtal apine. 
d) All of the above. 
e) (a) and (c). 
Volume 28 I Number 10 I October 2009 
Acc redited by the CPO &PI Progra m ../ 
Conclusion 
Unti l substant iated, neither efficacy nor speed of onset 
of act ion appea rs to be substantially altered in the newer 
generation ant idepressantsS The sea rch therefore cont in ues 
for a 'mag ic bul let' : the drug that wil l rap idly and safely meet 
the high expectat ions created by the word 'antidepressant'. 
Pharmacists have an essent ia l role in counsel ling patients 
regarding their antidepressant medications. Rea listic 
expectations should be discussed whilst still being mindful 
of the sign ificant percentage of pat ients who might show 
a powerful, and sometimes almost immediate, placebo 
response to ant idepressants. Furthermore, the benefits 
of psychotherapeutic intervention in conjuncti on with 
antidepressant therapy should also be emphasised. 
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fA score of 3 out of 4 attracts three quarters af a credit paint.) 
3. Identify the correct statement perta ining to ven lafaxin e. 
a) At low doses, venlafaxine's adverse effects are probably as a result 
of an effect on postsynaptic adrenergic receptors. 
bl At doses above 150 mg daily, adverse effects are associated with 
serotonergic receptors. 
c) Venlafaxine is safer in overdose than amitriptyline. 
dl Venlafaxine has a lower incidence of nausea and vomiting 
than SSR ls. 
e) Venlafaxine is an alpha-2-antagon ist on the presynaptic bulb. 
4. Ant idepressants have varying actions at the monoamine 
reuptake pump. Identify the incorrect statement with 
regard to this sta tement. 
a) Fluvoxamine only inhibits serotonin reuptake. 
b) Mirtazapine inhibits serotonin, noradrena line and 
dopamine reuptake. 
cl Reboxeti ne only inhibits noradrena line reuptake. 
d) Ouloxetine inhibits noradrenaline and serotoni n. 
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